Compare Abbott Laboratories (ABT) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Logitech International SA — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Logitech International SA trades at $97.15 (market cap $13.85B). The key difference: Abbott Laboratories is far larger — about 12.1× Logitech International SA's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | LOGI | |
|---|---|---|
Market Cap | $166.94B | $13.85B |
Sector | Health | Technology |
52-Week High | $136.62 | $126.69 |
52-Week Low | $82.57 | $85.84 |
Enterprise Value | $193.69B | $12.20B |
Dividend Yield | 2.63% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Logitech (LOGI) trades at $97.11, up 3.31% with strong profitability metrics including 43.2% gross margin and 32.78% ROE. The stock shows bearish technical signals despite recent earnings beats, with Q1 2026 EPS of $1.13 exceeding expectations. Recent developments include new gaming partnerships and product launches like the G3 Series and Mobi Fold mouse. Cash flow trends show operational strength with $843M generated in 2025, though net cash flow was slightly negative at -$18M.
Logitech presents a mixed outlook with robust fundamentals offset by technical weakness. The 26% upside to consensus price target of $121.33 offers potential, but bearish moving averages and competitive pressures in peripherals market pose risks. Enterprise momentum and AI-enabled products provide growth catalysts, though investor sentiment remains divided with equal buy/sell analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
